Efficacy and safety of bevacizumab in pretreated metastatic breast cancer: a systematic review and meta-analysis

Conclusions: Bevacizumab-containing chemothe rapy, in light of its favorable effects on clinical outcomes, could be a preferred therapeutic option for patients with MBC, for whom the disease must be rapidly relieved. Further studies are warranted for exploring the advantageous patients with the receipt of bevacizumab in multiline treatment.
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research